Articles

Texas Opens Detransition Clinic: Implications for Pharma

Texas has opened a detransition clinic, raising questions about its impact on the pharmaceutical landscape. This article explores key implications for B2B stakeholders.

The China Question: A Dividing Force in Biotech

The biotech industry faces a critical divide over China's role in drug development. This article examines the implications for pharma teams and investors.

FDA Approves AstraZeneca’s Baxdrostat for Hypertension

The FDA has approved AstraZeneca's baxdrostat for treating hypertension, marking a significant milestone in hypertension management. This article explores the implications for pharmaceutical stakeholders.

From Reach to Relevance: Transforming Pharma Marketing Strategies

This article explores the shift in pharma marketing from mere reach to meaningful relevance, highlighting key strategies for B2B readers.

Design Therapeutics and Vincentage: Key Data Insights

This article delves into the recent data from Design Therapeutics on Friedreich's ataxia and Vincentage's obesity results from China, highlighting their implications for the pharmaceutical industry.

Regeneron Secures $125M Parabilis Deal for Drug Targets

Regeneron has entered a significant $125M deal with Parabilis to target elusive drug targets. This partnership could reshape competitive dynamics in the pharmaceutical industry.

AstraZeneca Secures FDA Approval for Hypertension Drug

AstraZeneca has gained FDA approval for its new hypertension drug, marking a significant milestone in the pharmaceutical industry. This approval opens new avenues for investment and competition.

WakeMed – Atrium Health Merger: Implications for Pharma

The merger between WakeMed and Atrium Health is set to reshape the healthcare landscape. This article explores its implications for pharmaceutical teams and investors.

Regeneron's Phase 3 Skin Cancer Miss: Implications for LAG-3 Development

Regeneron's recent Phase 3 trial failure in skin cancer highlights ongoing challenges in LAG-3 research. This article examines the implications for the pharmaceutical industry.

Amgen's Commitment to Tavneos Amid Concerns in Japan

Amgen reaffirms its support for Tavneos despite a liver toxicity report from Japan. This article explores the implications for the pharmaceutical industry.

U.S. Bans Entry from Ebola-Affected Countries Amid Patient Identification

The U.S. has announced a travel ban from Ebola-affected countries following the identification of an American patient. This article explores the implications for the pharmaceutical sector.

Trump's CMS Expands Catastrophic Coverage on ACA Exchanges

This article discusses the recent changes by Trump's CMS regarding ACA exchanges and their potential impact on the pharmaceutical sector.

Ebola Outbreak: Testing Long-Shot Vaccines Amid Crisis

As the Ebola outbreak continues, experts are considering testing unapproved vaccines. This article delves into the implications for the pharmaceutical industry.

Why the WakeMed – Atrium Health Merger Matters for Pharma

The merger between WakeMed and Atrium Health signals significant changes in the healthcare landscape, impacting pharmaceutical strategies and investments.

Eli Lilly and Caitlin Clark: A New Era for Community Engagement

Eli Lilly collaborates with basketball star Caitlin Clark to revitalize sports courts in Indianapolis, promoting community health and engagement.

Eli Lilly's Community Engagement through Sports Initiatives

Eli Lilly collaborates with Caitlin Clark to revitalize sports courts in Indianapolis neighborhoods, promoting community health and engagement.

The Future of AI in Pharma Marketing

This article delves into CMI Media Group's predictions for AI in pharma marketing, highlighting key insights and implications for industry stakeholders.

STAT+: The Impact of the WakeMed – Atrium Health Merger

The merger between WakeMed and Atrium Health is set to reshape healthcare dynamics. This article explores its implications for pharmaceutical teams and investors.

Enhertu's Dual FDA Approvals: A Game Changer in Early Breast Cancer Treatment

Daiichi and AstraZeneca's Enhertu has received dual FDA approvals for early breast cancer, marking a significant milestone in oncology. This article explores the implications for investors and pharma teams.

Understanding the FDA: A Response to Marty Makary's Critique

This article examines the critiques made by Marty Makary regarding the FDA and clarifies key misunderstandings that could impact pharmaceutical strategies.